Emergent Biosolutions Inc. (NYSE:EBS) shares fell 5.7% during trading on Wednesday . The stock traded as low as $27.81 and last traded at $27.93, with a volume of 160,971 shares. The stock had previously closed at $29.63.

Several brokerages have recently commented on EBS. Cowen and Company reiterated a “buy” rating on shares of Emergent Biosolutions in a research note on Sunday, April 17th. Chardan Capital reiterated a “buy” rating on shares of Emergent Biosolutions in a research note on Monday, May 2nd. Zacks Investment Research downgraded Emergent Biosolutions from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 2nd. JPMorgan Chase & Co. reduced their target price on Emergent Biosolutions from $45.00 to $36.00 and set an “overweight” rating for the company in a research note on Friday, August 5th. Finally, Singular Research reduced their target price on Emergent Biosolutions from $44.00 to $40.00 and set a “buy” rating for the company in a research note on Tuesday, June 28th. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $40.00.

The stock has a market capitalization of $1.11 billion and a price-to-earnings ratio of 19.63. The firm has a 50 day moving average of $30.86 and a 200-day moving average of $36.24.

Emergent Biosolutions (NYSE:EBS) last posted its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by $0.01. The company earned $101.49 million during the quarter, compared to analyst estimates of $111.20 million. During the same quarter in the prior year, the business posted $0.36 earnings per share. The business’s revenue for the quarter was down 19.5% compared to the same quarter last year. Equities analysts predict that Emergent Biosolutions Inc. will post $1.55 earnings per share for the current year.

In related news, Director George A. Joulwan sold 4,700 shares of the company’s stock in a transaction that occurred on Monday, June 6th. The stock was sold at an average price of $44.12, for a total transaction of $207,364.00. Following the transaction, the director now directly owns 20,785 shares of the company’s stock, valued at approximately $917,034.20. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, major shareholder Fuad El-Hibri sold 25,000 shares of the company’s stock in a transaction that occurred on Thursday, May 12th. The stock was sold at an average price of $38.71, for a total value of $967,750.00. Following the transaction, the insider now directly owns 1,699,073 shares in the company, valued at $65,771,115.83. The disclosure for this sale can be found here.

Other hedge funds recently modified their holdings of the company. Rhumbline Advisers increased its stake in shares of Emergent Biosolutions by 6.4% in the fourth quarter. Rhumbline Advisers now owns 41,899 shares of the biopharmaceutical company’s stock valued at $1,676,000 after buying an additional 2,505 shares during the period. California Public Employees Retirement System increased its stake in shares of Emergent Biosolutions by 5.1% in the fourth quarter. California Public Employees Retirement System now owns 104,000 shares of the biopharmaceutical company’s stock valued at $4,161,000 after buying an additional 5,000 shares during the period. Cornerstone Capital Management Holdings LLC. increased its stake in shares of Emergent Biosolutions by 5.9% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 57,927 shares of the biopharmaceutical company’s stock valued at $2,317,000 after buying an additional 3,227 shares during the period. Bank of Montreal Can increased its stake in shares of Emergent Biosolutions by 346.9% in the fourth quarter. Bank of Montreal Can now owns 93,100 shares of the biopharmaceutical company’s stock valued at $3,725,000 after buying an additional 72,266 shares during the period. Finally, US Bancorp DE increased its stake in shares of Emergent Biosolutions by 6.9% in the fourth quarter. US Bancorp DE now owns 33,169 shares of the biopharmaceutical company’s stock valued at $1,327,000 after buying an additional 2,152 shares during the period.

Emergent BioSolutions Inc is a biopharmaceutical company that offers specialized products to healthcare providers and governments to address medical needs and emerging health threats. The Company develops, manufactures and delivers a portfolio of medical countermeasures primarily for government agencies in the areas of biological and chemical threats and emerging infectious diseases (EID).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.